Article 1
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.
Commission Implementing Regulation (EU) 2026/1826 of 28 July 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances aclonifen, amisulbrom, Bacillus amyloliquefaciens strain MBI 600, beflubutamid, clomazone, cyantraniliprole, cyprodinil, daminozide, dichlorprop-P, dimethachlor, fludioxonil, formetanate, fosetyl, isofetamid, metalaxyl, metazachlor, penconazole, phenmedipham, pirimicarb, pyraclostrobin and S-abscisic acid
Data as of 2026-08-06 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.
This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union .
ANNEX The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows: (1) Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 81, Pyraclostrobin, the date is replaced by ‘15 December 2026’; (2) in the sixth column, expiration of approval, of row 88, Phenmedipham, the date is replaced by ‘30 September 2027’; (3) in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘15 December 2027’; (4) in the sixth column, expiration of approval, of row 124, Pirimicarb, the date is replaced by ‘31 July 2027’; (5) in the sixth column, expiration of approval, of row 130, Cyprodinil, the date is replaced by ‘31 July 2027’; (6) in the sixth column, expiration of approval, of row 131, Fosetyl, the date is replaced by ‘31 January 2028’; (7) in the sixth column, expiration of approval, of row 133, Dichlorprop-P, the date is replaced by ‘31 October 2027’; (8) in the sixth column, expiration of approval, of row 147, Formetanate, the date is replaced by ‘30 September 2027’; (9) in the sixth column, expiration of approval, of row 158, Beflubutamid, the date is replaced by ‘31 July 2028’; (10) in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘30 September 2027’; (11) in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘31 December 2027’; (12) in the sixth column, expiration of approval, of row 215, Aclonifen, the date is replaced by ‘31 March 2029’; (13) in the sixth column, expiration of approval, of row 217, Metazachlor, the date is replaced by ‘31 May 2029’; (14) in the sixth column, expiration of approval, of row 284, Dimethachlor, the date is replaced by ‘31 March 2029’; (15) in the sixth column, expiration of approval, of row 287, Penconazole, the date is replaced by ‘15 February 2029’; (16) in the sixth column, expiration of approval, of row 304, Metalaxyl, the date is replaced by ‘30 June 2029’; (2) Part B is amended as follows: (1) in the sixth column, expiration of approval, of row 65, S-abscisic acid, the date is replaced by ‘15 April 2029’; (2) in the sixth column, expiration of approval, of row 69, Amisulbrom, the date is replaced by ‘15 March 2030’; (3) in the sixth column, expiration of approval, of row 99, Cyantraniliprole, the date is replaced by ‘14 March 2030’; (4) in the sixth column, expiration of approval, of row 100, Isofetamid, the date is replaced by ‘15 March 2030’; (5) in the sixth column, expiration of approval, of row 101, Bacillus amyloliquefaciens strain MBI 600, the date is replaced by ‘1 December 2029’.
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.